BioCentury | Aug 23, 2004
Company News

Proacta Therapeutics Ltd. management update

...Business: Cancer Hired: Paul Cossum as president and CEO, formerly EVP of drug development at NewBiotics Inc. WIR...
BioCentury | Aug 16, 2004
Company News

Proacta hires Cossum as CEO

...hired Paul Cossum as president and CEO. He was previously EVP of drug development at NewBiotics Inc. BC...
BioCentury | Jul 12, 2004
Company News

NewBiotics, Theratechnologies deal

...Montreal, Quebec), completed its previously announced acquisition of cancer company NewBiotics (see BioCentury, June 14). NewBiotics...
...ownership interest in Celmed, and TH's ownership in Celmed was reduced to 42% from 59.7%. NewBiotics Inc....
BioCentury | Jun 14, 2004
Company News

NewBiotics, Theratechnologies deal

...TH's majority owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), will acquire cancer company NewBiotics. NewBiotics shareholders...
...ownership interest in Celmed, which will reduce TH's ownership in Celmed to 42.0% from 59.7%. NewBiotics'...
...to fund clinical development. As of Feb. 29, Celmed had C$28.5 million (US$21.1) in cash. NewBiotics Inc....
BioCentury | Jun 7, 2004
Company News

Celmed to acquire NewBiotics

...subsidiary Celmed BioSciences will acquire cancer company NewBiotics (San Diego, Calif.) in a stock deal. NewBiotics...
...ownership interest in Celmed , which will reduce TH's Celmed stake to 42% from 59.7%. NewBiotics'...
BioCentury | Jan 12, 2004
Company News

Cryptome management update

...Proteomics Hired: Jeffrey Travis as CEO, formerly head of corporate development and strategic planning at NewBiotics Inc. WIR...
BioCentury | Jun 2, 2003
Company News

MethylGene management update

...Quebec Business: Cancer Hired: Nafsika Georgopapadakou as VP of infectious diseases, formerly senior director at NewBiotics Inc. WIR...
BioCentury | Nov 25, 2002
Clinical News

Thymectacin: Phase I

...chemotherapy showed Thymectacin was well tolerated at all dose levels from 200-2,000 mg/m2. In addition, NewBiotics...
...dose has not been determined yet. Data were presented at the AACR-NCI-EORTC meeting in Frankfurt. NewBiotics Inc....
BioCentury | Nov 11, 2002
Company News

ChromaVision, NewBiotics deal

...use its ACIS digital imaging system to analyze tissue samples from colon cancer patients in NewBiotics’...
...will receive a fee per specimen. ChromaVision Medical Systems Inc. (CVSN), San Juan Capistrano, Calif. NewBiotics Inc....
BioCentury | Nov 6, 2002
Company News

ChromaVision, NewBiotics imaging deal

...samples from colon cancer patients enrolled in NewBiotics' Phase I and II trials of Thymectacin. NewBiotics...
Items per page:
1 - 10 of 29
BioCentury | Aug 23, 2004
Company News

Proacta Therapeutics Ltd. management update

...Business: Cancer Hired: Paul Cossum as president and CEO, formerly EVP of drug development at NewBiotics Inc. WIR...
BioCentury | Aug 16, 2004
Company News

Proacta hires Cossum as CEO

...hired Paul Cossum as president and CEO. He was previously EVP of drug development at NewBiotics Inc. BC...
BioCentury | Jul 12, 2004
Company News

NewBiotics, Theratechnologies deal

...Montreal, Quebec), completed its previously announced acquisition of cancer company NewBiotics (see BioCentury, June 14). NewBiotics...
...ownership interest in Celmed, and TH's ownership in Celmed was reduced to 42% from 59.7%. NewBiotics Inc....
BioCentury | Jun 14, 2004
Company News

NewBiotics, Theratechnologies deal

...TH's majority owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), will acquire cancer company NewBiotics. NewBiotics shareholders...
...ownership interest in Celmed, which will reduce TH's ownership in Celmed to 42.0% from 59.7%. NewBiotics'...
...to fund clinical development. As of Feb. 29, Celmed had C$28.5 million (US$21.1) in cash. NewBiotics Inc....
BioCentury | Jun 7, 2004
Company News

Celmed to acquire NewBiotics

...subsidiary Celmed BioSciences will acquire cancer company NewBiotics (San Diego, Calif.) in a stock deal. NewBiotics...
...ownership interest in Celmed , which will reduce TH's Celmed stake to 42% from 59.7%. NewBiotics'...
BioCentury | Jan 12, 2004
Company News

Cryptome management update

...Proteomics Hired: Jeffrey Travis as CEO, formerly head of corporate development and strategic planning at NewBiotics Inc. WIR...
BioCentury | Jun 2, 2003
Company News

MethylGene management update

...Quebec Business: Cancer Hired: Nafsika Georgopapadakou as VP of infectious diseases, formerly senior director at NewBiotics Inc. WIR...
BioCentury | Nov 25, 2002
Clinical News

Thymectacin: Phase I

...chemotherapy showed Thymectacin was well tolerated at all dose levels from 200-2,000 mg/m2. In addition, NewBiotics...
...dose has not been determined yet. Data were presented at the AACR-NCI-EORTC meeting in Frankfurt. NewBiotics Inc....
BioCentury | Nov 11, 2002
Company News

ChromaVision, NewBiotics deal

...use its ACIS digital imaging system to analyze tissue samples from colon cancer patients in NewBiotics’...
...will receive a fee per specimen. ChromaVision Medical Systems Inc. (CVSN), San Juan Capistrano, Calif. NewBiotics Inc....
BioCentury | Nov 6, 2002
Company News

ChromaVision, NewBiotics imaging deal

...samples from colon cancer patients enrolled in NewBiotics' Phase I and II trials of Thymectacin. NewBiotics...
Items per page:
1 - 10 of 29